“I unmatched him,” she says. “Obviously didn’t send it.” To conclude, Dr. Buchanan said she hopes her surprise prescription ...

Here’s what you need to know. Vyvanse is the brand name of the drug lisdexamfetamine dimesylate. According to the Mayo Clinic, the drug is used to treat both ADHD in adults and children 6 years ...

Pharmac is funding Lisdexamfetamine for ADHD and narcolepsy, benefiting more than 6000 people from December. Pharmac is ...

Pharmac is funding new medicine for people with attention deficit hyperactivity disorder (ADHD) and narcolepsy, and removing ...

From 1 December 2024, Pharmac is also removing the renewal criteria for methylphenidate, dexamfetamine and modafinil, medicines used to treat ADHD and narcolepsy. This means that once an initial ...

Lisdexamfetamine dimesylate (Vyvanse; New River Pharmaceuticals/Shire), a prodrug of D-amphetamine, was approved by the US FDA in February 2007 for the treatment of ...

The FDA predicts that medical use of amphetamine, methylphenidate and lisdexamfetamine to treat ADHD and other diagnoses in ...

Pharmac has announced it'll fund new stimulant medicine lisdexamfetamine from December. The medicine -- branded as Vyvanse -- is taken once a day. Chief medical officer, David Hughes, says it's a ...

Taking “study drugs” like Adderall without a diagnosis is not only dangerous in itself, but can lead to other drug use and a decline in mental health, according to new research from Binghamton ...

Get detailed information on Lisdexamfetamine, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...

Lisdexamfetamine dimesylate 10mg, 20mg, 30mg, 40mg, 50mg, 60mg; strawberry-flavored. 10 mg – white to off-white round shaped tablet debossed with ‘10’ on one side and ‘S489’ on the other ...

Review the side-effects of Lisdexamfetamine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication.